North & North · Research
Two repair peptides, finally measured together
Your stomach makes one of these and your cells are full of the other. BPC-157 is a fragment pulled from a protein that protects tissue. TB-500 is a synthetic copy of one that holds cells together. Both are studied in repair, and in 2026 they were finally tested side by side.
The question everyone asks
Two peptides studied in the same territory, tested separately and as a pair. The pair did not come out ahead.
Most material about these two treats them as a set, so the 2026 study is worth knowing about. It is preclinical, and it ran four arms: a control, each compound on its own, and the two combined. On the measures it recorded, tendon strength and the organisation of the healing tissue, TB-500 showed the clearest separation from control, BPC-157 moved the same way without reaching significance on its totals, and the combination did not add anything over either compound by itself. That is one preclinical study on one kind of repair, and it is the only direct comparison published so far, which is exactly why it is worth reading rather than taking on trust.
Side by side
| Comparison point | BPC-157 | TB-500 |
|---|---|---|
| Where it comes from | A fragment of a protein found in the stomach. | A synthetic copy of Thymosin Beta-4, full 43 amino acid sequence. |
| What it is studied for | Tendon, ligament, muscle and gut repair. | Cell movement and tissue repair, plus cardiac research. |
| How it is described as working | Nudging growth factor signaling and blood vessel response already underway. | Acting on actin, the scaffolding that governs how cells move. |
| Human studies underway | A placebo controlled trial in hamstring strain, recruiting since February 2026. | A Phase II study in acute myocardial infarction, beginning May 2026. |
| In the 2026 preclinical head to head | Moved in the same direction as TB-500 without reaching significance on the totals. | Reached statistical significance on tendon strength and tissue architecture. |
| What North & North supplies | Research material only, 5mg, >99% purity. | Research material only, 10mg, >99% purity. |
Reading the research
BPC-157
The broader body of work. If the question is how a repair signal behaves across several kinds of tissue at once, muscle, tendon, ligament, bone and gut, this is where the published record is widest, and it has a placebo controlled human trial recruiting now.
TB-500
The one with the cleaner mechanism. Actin handling is a specific, measurable thing, which is part of why it separated from control most clearly in the head to head. Its human work sits in cardiac research rather than sports injury.
Current work
Both compounds moved into human study in 2026, which is the shift worth watching. A placebo controlled trial of BPC-157 in hamstring strain has been recruiting since February, and a Phase II study of TB-500 in acute myocardial infarction began in May. Neither has reported.
The head to head sits alongside that human work rather than above it. It is a single preclinical study on one kind of repair, so it establishes nothing about people. What it does give, for the first time, is the two compounds measured under the same conditions. Read it for the comparison, not for a conclusion.
Every source below was opened and read before it was cited. Nothing on this page is a claim about what either compound does.
Common questions
They are studied in the same territory but they are not related molecules. BPC-157 is a fragment taken from a protein your stomach makes to protect tissue. TB-500 is a synthetic copy of a protein your cells already keep in quantity to hold their internal scaffolding together.
Some study designs do. A 2026 preclinical head to head tested each on its own and both in combination, and the combination did not outperform either one alone on the measures it recorded. That is one study, and it establishes nothing about people, but it does make each a cleaner subject on its own than the two together.
They are close, and they are different in shape. BPC-157 has the larger body of work overall and a placebo controlled human trial now recruiting. TB-500 has fewer studies but a Phase II human study underway and the stronger showing in the 2026 head to head.
No. Some material sold under the TB-500 name is a short fragment of Thymosin Beta-4. North & North supplies the full 43 amino acid sequence, and findings for one do not automatically transfer to the other.
Neither is an approved drug. Both are supplied by North & North as research material only, not for human consumption or therapeutic use.
Go deeper
Catalog access
Create a quick and easy free account to shop BPC-157 and TB-500 and other peptides.
Free to create. You will verify your email address before the catalog opens.
The statements made on this website have not been evaluated by the U.S. Food and Drug Administration. Products offered through this website and information presented here are not intended to diagnose, treat, cure, or prevent any disease or medical condition. North & North LLC is not a pharmacy, compounding pharmacy, compounding facility, medical provider, or outsourcing facility. All products are sold strictly for research, laboratory, or analytical purposes only and are not intended for human consumption. Customers are solely responsible for compliance with all applicable federal, state, and local laws governing the purchase, possession, handling, and use of research-use compounds.
